Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $81,000.

  • Contineum Therapeutics' Depreciation & Amortization (CF) rose 30.65% to $81,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $355,000, marking a year-over-year increase of 57.78%. This contributed to the annual value of $300,000 for FY2024, which is 50.00% up from last year.
  • Per Contineum Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $81,000 for Q3 2025, which was up 2.53% from $79,000 recorded in Q2 2025.
  • Over the past 5 years, Contineum Therapeutics' Depreciation & Amortization (CF) peaked at $117,000 during Q4 2024, and registered a low of $42,000 during Q2 2023.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $62,000 (2024), whereas its average is $67,091.
  • The largest annual percentage gain for Contineum Therapeutics' Depreciation & Amortization (CF) in the last 5 years was 178.57% (2024), contrasted with its biggest fall of 16.44% (2024).
  • Contineum Therapeutics' Depreciation & Amortization (CF) (Quarterly) stood at $42,000 in 2023, then soared by 178.57% to $117,000 in 2024, then soared by 30.65% to $81,000 in 2025.
  • Its Depreciation & Amortization (CF) stands at $81,000 for Q3 2025, versus $79,000 for Q2 2025 and $78,000 for Q1 2025.